A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated <i>NRAS<sup>Q61R/K/L</sup></i> Mutant Melanoma (TraMel-WT).

A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRAS^Q61R/K/L Mutant Melanoma (TraMel-WT).

Awada, Gil; Schwarze, Julia Katharina; Tijtgat, Jens; Fasolino, Giuseppe; Everaert, Hendrik; Neyns, Bart.

Afiliação

Awada G; Department of Medical Oncology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), 1090 Brussels, Belgium.
Schwarze JK; Department of Medical Oncology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), 1090 Brussels, Belgium.
Tijtgat J; Department of Medical Oncology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), 1090 Brussels, Belgium.
Fasolino G; Department of Ophthalmology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), 1090 Brussels, Belgium.
Everaert H; Department of Nuclear Medicine, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), 1090 Brussels, Belgium.
Neyns B; Department of Medical Oncology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), 1090 Brussels, Belgium.

Cancers (Basel) ; 13(9)2021 Apr 22.

Article em En | MEDLINE | ID: mdl-33921947